InVivo Therapeutics Announces Promotions in Technical Operations

InVivo Therapeutics Announces Promotions in Technical Operations

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV), a pioneering biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries, today announced that William D'Agostino has been promoted to Vice President, Manufacturing & Engineering and Robert Ham has been promoted to Senior Director, Quality. These promotions are effective January 1, 2014.

"These two executives have led the charge to bring our scaffold manufacturing process in-house in order to better control quality, costs and availability of material for our first clinical trial, which is scheduled to be ready to enroll patients next quarter. We are grateful for their skill and leadership."
Interim Chief Executive Officer Michael Astrue said, "These two executives have led the charge to bring our scaffold manufacturing process in-house in order to better control quality, costs and availability of material for our first clinical trial, which is scheduled to be ready to enroll patients next quarter. We are grateful for their skill and leadership."

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a pioneering biomaterials company with unique technologies for drug delivery with a focus on treatment of spinal cord injuries. The Company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011 the Company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit, www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties, and include statements regarding the Company's expectations with respect to the commencement of human clinical trials for the scaffold product and the impact of the Company's efforts with respect to the manufacturing of the scaffolds. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to obtain FDA approval of its revised protocol and the timing thereof; the identification of appropriate clinical sites; the Institutional Review Board process; the Company's ability to enter into partnerships; the Company's ability to obtain FDA approval to commercialize its products; the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in our filings with the SEC, including our Form 10-K and 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

Contacts

InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Director, Investor Relations
[email protected]

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.